Neurodegenerative Diseases Drugs Market to Hit US$ 85.0 Bn by 2032, Reports Persistence Market Research

Neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis (MS) continue to challenge global healthcare systems due to their chronic nature, progressive symptoms, and limited treatment options. With the market poised to grow from US$ 58.4 Bn in 2025 to US$ 85.0 Bn by 2032 at a CAGR of 5.5%, pharmaceutical innovation and precision medicine are ushering in a new era of disease-modifying therapies. According to Persistence Market Research, this evolving landscape reflects a dynamic interplay between demographic trends, drug innovation, and regulatory agility.

The neurodegenerative diseases drugs market is being propelled by an aging global population, high incidence rates, and increasing investment in neurological research. Multiple sclerosis leads the disease indication segment, while North America dominates geographically, driven by advanced diagnostic infrastructure and robust reimbursement frameworks. Immunomodulators are expected to hold a commanding 43.5% share in 2025, signaling a shift toward therapies that modify disease progression rather than simply alleviate symptoms.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35538

✅Key Highlights from the Report

➤ The market is projected to grow at a 5.5% CAGR between 2025 and 2032, reaching US$ 85.0 Bn.
➤ Immunomodulators will account for 43.5% of the total drug class share in 2025.
➤ Multiple sclerosis is the leading indication due to strong clinical and funding support.
➤ North America remains the dominant regional market, driven by FDA approvals and Medicare support.
➤ Rising focus on stem cell-based regenerative therapies is creating new growth avenues.
➤ Diagnostic advancements, such as PET and CSF biomarker assays, are expanding treatment eligibility.

✅Market Segmentation: Drug Classes and Disease Indications

The market is segmented by drug class into immunomodulators, dopamine agonists, interferons, decarboxylase inhibitors, and others. Immunomodulators, due to their efficacy in halting inflammatory pathways, are especially dominant in conditions like multiple sclerosis. These agents work by correcting immune system dysfunction, and are increasingly paired with biomarker-based targeting to improve outcomes. Dopamine agonists are also gaining traction in Parkinson's disease treatment due to fewer long-term complications than levodopa.

Based on disease indication, the market is classified into multiple sclerosis, Alzheimer's disease, Parkinson's disease, Spinal Muscular Atrophy (SMA), and others. Multiple sclerosis leads with approximately 62.6% share in 2025, benefiting from clear endpoints, robust funding, and widespread availability of DMTs. Meanwhile, Alzheimer's continues to rise in importance due to its massive patient burden, pushing it to the center of pharmaceutical innovation and public health initiatives.

✅Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/neurodegenerative-disease-drugs-market.asp

✅ Regional Insights

North America is set to lead the global neurodegenerative diseases drugs market with 51.8% share in 2025, fueled by FDA-approved treatments, advanced diagnostics, and CMS reimbursement reforms. The approval of Eisai and Biogen's Leqembi has catalyzed U.S. policy support for disease-modifying therapies, improving market conditions.

Europe, though cautious with reimbursement approvals, is bolstering innovation through initiatives like the Innovative Health Initiative (IHI). Conditional EMA approvals and growing investment in Real-World Data platforms signify Europe's commitment to evidence-driven adoption of neurodegenerative drugs.

✅ Market Drivers

The primary driver of growth in this market is the increasing emphasis on early diagnosis. The approval of lecanemab for early-stage Alzheimer's has significantly shifted the diagnostic landscape. Healthcare providers are investing in imaging and fluid biomarker tests, expanding the population eligible for early intervention. Persistence Market Research notes that early-stage targeting is enabling pharmaceutical companies to develop drugs aimed at preventing irreversible neuronal damage.

✅ Market Restraints

A major restraint remains the lack of diagnostic infrastructure and biased reimbursement models. Many healthcare systems still rely heavily on symptomatic treatments, hindering adoption of novel therapies. Biomarker-based diagnostics, while crucial, are often costly and inaccessible. Moreover, even when drugs like Leqembi receive approval, limited coverage and regional discrepancies prevent widespread uptake.

✅ Market Opportunities

One of the most promising opportunities lies in stem cell-based regenerative therapies. Stem cell research is opening up pathways for drugs aimed at neuronal repair rather than symptom control. Pharmaceutical companies are partnering with biotech firms to develop combination therapies that enhance cell engraftment. Trials like BlueRock Therapeutics' dopamine-producing cell therapy for Parkinson's highlight this potential, showing improved motor function in early-stage studies.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35538

✅ Reasons to Buy the Report

✔ Gain comprehensive insights into a rapidly evolving high-growth pharmaceutical segment.
✔ Understand market dynamics, including innovation drivers and reimbursement frameworks.
✔ Access region-specific analysis to inform global expansion strategies.
✔ Evaluate key drug classes and disease indications shaping investment priorities.
✔ Stay updated with recent approvals, clinical developments, and strategic collaborations.

✅Company Insights

✦ Biogen
✦ Pfizer, Inc.
✦ Hoffmann-La Roche Ltd.
✦ Merck & Co., Inc.
✦ Novartis AG
✦ Sanofi
✦ Teva Pharmaceutical Industries Ltd.
✦ Orion Pharma
✦ UCB S.A
✦ ACADIA Pharmaceuticals Inc.
✦ Lundbeck A/S
✦ Mitsubishi Tanabe Pharma Corporation
✦ Others

✅Key Developments in the Market

✦ In July 2025, Klotho Neurosciences secured FDA Orphan Drug Designation for KLTO-202, a novel gene therapy for ALS, promising market exclusivity and financial incentives.
✦ In March 2025, Alpha Cognition Inc. launched ZUNVEYL, a treatment for mild to moderate Alzheimer's, aimed at enhancing accessibility and cognitive outcomes.

✅Final Thoughts

The neurodegenerative diseases drugs market is entering a transformative phase. Advances in early diagnosis, the approval of disease-modifying drugs, and expanding R&D into cell-based therapies are reshaping how these devastating conditions are managed. However, real-world success will depend on the global alignment of regulatory, diagnostic, and reimbursement frameworks. With North America taking the lead, and Asia Pacific following with robust policy support, pharmaceutical companies must now align pipeline strategies with precision-based, multi-modal treatments.

As noted by Persistence Market Research, the market's trajectory signals more than just financial opportunity-it represents hope for millions affected by degenerative neurological disorders worldwide. By 2032, the shift from symptomatic management to biologic and regenerative intervention could become the new clinical standard, redefining the future of neurological care.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.